Jing Yang

机构：China Pharmaceutical University, Shandong Tumor Hospital, Second Hospital of Shandong University, Nanyang Normal University, Anyang Normal University, Shandong First Medical University · ORCID：0009-0003-2199-8623

发表论文 77 篇 · 总被引 2625 次 · h-index 24

代表论文

• Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial (2022 · The Lancet Oncology · 被引 769)
• Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 278)
• A New Ratiometric Design Strategy Based on Modulation of π-Conjugation Unit for Developing Fluorescent Probe and Imaging of Cellular Peroxynitrite (2022 · Analytical Chemistry · 被引 41)
• Excessive SOX8 reprograms energy and iron metabolism to prime hepatocellular carcinoma for ferroptosis (2023 · Redox Biology · 被引 26)
• Synergistic bioremediation of petroleum-contaminated soil using immobilized consortium of Rhodococcus rhodochrous and Bacillus subtilis laccase (2024 · Journal of Environmental Management · 被引 18)
• Development of novel salicylic acid–donepezil–rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer’s disease (2023 · Journal of Enzyme Inhibition and Medicinal Chemistry · 被引 15)